DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Information source: Dana-Farber Cancer Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Prostate Cancer

Intervention: Abiraterone acetate (Drug); Dutasteride (Drug); Prednisone (Drug)

Phase: Phase 2

Status: Active, not recruiting

Sponsored by: Mary-Ellen Taplin, MD

Official(s) and/or principal investigator(s):
Mary-Ellen Taplin, M.D., Principal Investigator, Affiliation: Dana-Farber Cancer Institute


The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic disease. This study will also help determine the side effects of the study treatment and how often they occur.

Clinical Details

Official title: Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To analyze possible AR related mechanisms of abiraterone acetate resistance in serial CRPC metastasis biopsies.

Secondary outcome:

Assessment of serum levels of testosterone, dihydrotestosterone and androgen precursors at baseline and at progression.

Assessment of PSA response

Assessment of PSA response duration on Abiraterone acetate-prednisone/Dutasteride

To assess response of measurable disease if present

To assess time to progression of bone lesions or measurable disease (RECIST)

Assessment of toxicity of Abiraterone acetate and Dutasteride

To correlate presence of AR amplification

To measure serum androgens and CTCs

Evaluation of methods for using CTCs for RNA based expression profiling of AR and AR regulated genes as an exploratory endpoint.

Detailed description: Patients will receive abiraterone acetate and prednisone orally, once daily for 2 months (2 cycles) on an outpatient basis. At the start of cycle 3, dutasteride will be taken once daily. Patients will return to the clinic on Day 14 of the first 3 cycles for routine blood tests. Patients will come to the clinic every 12 weeks for a CT scan and/or x-ray of the chest, CT scan or MRI of the abdomen and pelvis, bone scan, and blood test for testosterone and other specialized blood test.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.


Inclusion Criteria:

- Diagnosis of adenocarcinoma of the prostate

- Castrate resistant disease

- Metastatic disease

- Normal organ and marrow function

- Subjects with partners of childbearing potential must be willing to use adequate

methods of birth control Exclusion Criteria:

- Uncontrolled intercurrent illness

- Uncontrolled hypertension

- Active or symptomatic viral hepatitis or chronic liver disease

- History of pituitary or adrenal dysfunction

- Clinically significant heart disease

- History of a different malignancy unless disease-free for at least 5 years

- Known brain metastasis

- History of gastrointestinal disorders

- Prior therapy with abiraterone acetate

- HIV-positive individuals on antiretroviral therapy

- Requirement for steroid use greater than the equivalent of 5 mg of prednisone daily

- Atrial fibrillation or other cardiac arrhythmia requiring therapy

- Thromboembolism in the last 6 months

Locations and Contacts

Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, United States

Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States

Seattle Cancer Care Alliance, Seattle, Washington 98109, United States

University of Washington Medical Center, Seattle, Washington 98195, United States

Additional Information

Starting date: September 2011
Last updated: June 2, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017